EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence . J. Can. Res. Updates [Internet]. 2012 Jan. 28 [cited 2026 May 5];1(1): 102-107. Available from: https://www.neoplasiaresearch.com/index.php/jcru/article/view/380